Researchers Discover That a Blood Thinner Significantly Reduces the Risk of Death After Non-Cardiac Surgery
First randomized controlled trial to evaluate a treatment for MINS
Researchers in Hamilton have discovered that a blood-thinning drug, dabigatran, significantly reduces the risk of death, heart attack, stroke, and other heart or blood-vessel complications in patients who have a heart injury following major, non-cardiac surgery.
Every year, approximately eight million people world-wide develop a condition called myocardial injury after non-cardiac surgery (MINS), which refers to damage incurred to the tissue of the heart in response to the stress of surgery on the body. The condition affects patients undergoing major procedures such as a hip or knee replacement, bowel resection, or abdominal aortic aneurysm repair, and can lead to severe complications including heart attack, stroke, blood clots, amputations, and death.
Click here to read more.
1st Annual Aspen Conference on Pediatric Cerebrovascular Disease and Stroke
July 16-20, 2018; Snowmass Village, CO
2018 Neurosafe Symposium
August 2-3, 2018; Minneapolis
2018 Tennessee Neurological Society Annual Meeting
August 3-4, 2018; Franklin, TN
2018 From Cranial to Spine: An Overview of Neurological Topics for the Advanced Practice Provider
August 8-11, 2018; Los Angeles
2018 Managing Coding and Reimbursement Challenges
August 9-11, 2018; Chicago